Overdone, page-18

My theory about the $2M. As we know its money received but not yet "earned" which is why its still being treated as deferred or unearned revenue. The company has to deliver a good or service in order to book the revenue as earned. Now. I thought it may have been a milestone payment received this quarter from Hikma triggered by first sales of Unifill in the last quarter (Sept Qtr). They thought they could amortise it in the Sept Quarter because that's when they actually delivered the Unifill syringes. Alternatively. If it relates to milestone payments from Hikma or Sanofi received in the March Qtr (the last quarter they actually received any milestone payment) then it might mean the company has not delivered a good or service due in the Sept Qtr which means they cant book the revenue as earned in the Sept Qtr. As far as we know, the only major target in the Sept Qtr was Unifill sales to Hikma and that was achieved.